Table 4.
Concomitant Medications in the Mirror-Image Periods
| Medication Use Before CNS Stimulant Medication | Medication Use During CNS Stimulant Medication | P Value | |
|---|---|---|---|
| FGAs | |||
| Low-potencya | 210 (34.71%) | 158 (26.11%) | <.001 |
| Mid-potencyb | 54 (8.93%) | 42 (6.94%) | .073 |
| High-potencyc | 28 (4.63%) | 26 (4.30%) | .851 |
| SGAs | |||
| Amisulprid | 14 (2.31%) | 8 (1.32%) | .180 |
| Aripiprizol | 113 (18.68%) | 109 (18.02%) | .708 |
| Clozapine | 30 (4.96%) | 25 (4.13%) | .332 |
| Olanzapine | 108 (17.85%) | 100 (16.53%) | .374 |
| Quetiapine | 162 (26.78%) | 164 (27.11%) | .928 |
| Risperidone | 106 (17.52%) | 79 (13.06%) | <.001 |
| Ziprazidone | 43 (7.11%) | 25 (4.13%) | .001 |
| TCAs | 32 (5.29%) | 22 (3.64%) | .0525 |
| SSRIs | 212 (35.04%) | 170 (28.10)% | <.001 |
| Benzodiazepines | 252 (41.65%) | 231 (38.18%) | .035 |
Note: SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants; FGAs, first-generation antipsychotics; SGAs, second-generation antipsychotics; CNS, central nervous system.
aIncluding chlorpromazine, chlorprothixene, levomepromazine, melperone, pipamerone, and sulpiride.
bIncluding periciazine, perphenazine, prochlorperazine, and zuclopenthixol.
cIncluding flupentixol, fluphenazine, haloperidol, and pimozide.